20th Nov 2018 15:28
RNS Number : 9478H
Indivior PLC
20 November 2018
INDIVIOR MAKES STATEMENT ON COURT DECISION
"Indivior is disappointed that the U.S. Court of Appeals for the Federal Circuit has vacated the preliminary injunction against Dr. Reddy's Laboratories ("DRL"). Indivior will continue to vigorously pursue ongoing infringement cases against DRL to protect its SUBOXONE® (buprenorphine and naloxone) Sublingual Film patent portfolio.
The Company is in the process of interpreting the ruling in its entirety and will issue a statement on its implications once this review has been completed."
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Related Shares:
Indivior